Avalon globocare receives notice from nasdaq regarding delayed quarterly report

Freehold, n.j., may 24, 2024 (globe newswire) -- avalon globocare corp. (“avalon” or the “company”) (nasdaq: albt), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “notice”) on may 22, 2024 from the nasdaq stock market llc (“nasdaq”) stating that the company is not in compliance with the requirements for continued listing under nasdaq listing rule 5250(c)(1) (the “listing rule”) because the company has not yet filed its quarterly report on form 10-q for the fiscal quarter ended march 31, 2024 (the “quarterly report”) with the securities and exchange commission (the “sec”).
ALBT Ratings Summary
ALBT Quant Ranking